01—Abstract
Summary
Summary of the 8-K filed June 3, 2024. Cited figures are marked; the original filing is the authoritative source.
On June 3, 2024, Becton, Dickinson and Company (BD) disclosed a definitive agreement to acquire Edwards Lifesciences' Critical Care product group for $4.2 billiona in cash.
Critical Care is a high-growth advanced patient monitoring business that invented the hemodynamic monitoring category, generated more than $900 millionb in 2023 revenue, employs about 4,500 people (mostly in Irvine, California), and has a reported 5-year revenue CAGR of roughly 7% with about 80% recurring revenue. The business will operate as a separate unit within BD's Medical segment, led by Katie Szyman. BD expects the deal to be immediately accretive to revenue growth, adjusted gross margin, adjusted operating margin, and adjusted EPS.
Management projects durable revenue growth of about 6%c to 7%, year-one adjusted gross margin of at least 60%, and adjusted operating margins of at least 25% that rise over time. Moderate cost synergies are expected mainly from cost of goods sold, supply chain, and G&A. The company describes the deal as a strong return profile that exceeds its cost of capital well ahead of typical benchmarks.
The transaction is funded with roughly $1 billiond of cash and $3.2 billion of new debt. Pro forma net leverage at closing is expected to be about 3x, with a plan to return to the 2.5x long-term target within 12 to 18 months through free cash flow debt repayment.
Closing is expected before the end of calendar 2024, subject to customary regulatory reviews and closing conditions. Investors should weigh the near-term leverage increase and integration execution against the growth and margin profile of the acquired business.
02—Key points
Key Highlights
- Acquisition of Edwards Lifesciences' Critical Care product group for $4.2 billion in all-cash consideration.
- Critical Care generated more than $900 million in 2023 revenue, with a 5-year revenue CAGR of about 7% and roughly 80% recurring revenue.
- Management expects immediate accretion to revenue growth, adjusted gross margin, adjusted operating margin, and adjusted EPS, with immediate and meaningful EPS accretion in year one.
- Projected long-term durable revenue growth of about 6% to 7%, with year-one adjusted gross margin of at least 60% and adjusted operating margin of at least 25%.
- Funding of approximately $1 billion cash and $3.2 billion new debt; net leverage of about 3x at close, targeting the 2.5x long-term level within 12 to 18 months.
- Critical Care becomes a separate business unit within BD's Medical segment, based in Irvine, California, led by Katie Szyman and reporting to Mike Garrison.
- Expected close before the end of calendar 2024, subject to customary regulatory clearances and closing conditions.
03—Questions
Frequently Asked Questions
Why is BD acquiring Critical Care?
BD says Critical Care expands its smart connected care portfolio with leading hemodynamic and monitoring technologies, AI-enabled clinical decision tools, and an innovation pipeline. BD also expects growth from its global footprint, deeper penetration of existing and new hospital customers, and application of its BD Excellence operating system.
How will the deal affect BD's financial profile?
BD expects the acquisition to be immediately accretive to revenue growth, adjusted gross and operating margins, and adjusted EPS. The company projects durable revenue growth of about 6% to 7%, with adjusted gross margin of at least 60% and adjusted operating margin of at least 25% in year one, expanding over time.
How will BD pay for the acquisition and what happens to its leverage?
BD will fund the deal with about $1 billion of cash and $3.2 billion of new debt. Net leverage is expected to rise to about 3x at closing, and BD plans to return to its 2.5x long-term net leverage target within 12 to 18 months mainly through free cash flow debt repayment.
When is the transaction expected to close and what could prevent it?
BD expects closing before the end of calendar 2024. Completion is subject to customary regulatory reviews and closing conditions, and the company's forward-looking statements flag risks including regulatory delays, integration challenges, and failure to realize expected synergies.
How will Critical Care be integrated into BD?
Critical Care will operate as a separate business unit within BD's Medical segment and keep its Irvine, California presence. Katie Szyman, corporate vice president of Critical Care since 2015, will lead the unit and report to Mike Garrison, executive vice president and president of the BD Medical segment.
04—Continue